Chengdu Easton Biopharmaceuticals Co Ltd
Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; A… Read more
Chengdu Easton Biopharmaceuticals Co Ltd (688513) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.021x
Based on the latest financial reports, Chengdu Easton Biopharmaceuticals Co Ltd (688513) has a cash flow conversion efficiency ratio of 0.021x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥61.35 Million) by net assets (CN¥2.87 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Chengdu Easton Biopharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Chengdu Easton Biopharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Chengdu Easton Biopharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chengdu Easton Biopharmaceuticals Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Anche Technologies Co Ltd
SHE:300572
|
0.005x |
|
AMN Healthcare Services Inc
NYSE:AMN
|
0.035x |
|
First National of Nebraska Inc
PINK:FINN
|
N/A |
|
Engie Energia Chile SA
SN:ECL
|
0.025x |
|
Hefei Jianghang Aircraft Equipment Corporation Ltd
SHG:688586
|
-0.030x |
|
Ticon Freehold and Leasehold Real Estate Investment Trust
BK:FTREIT
|
0.011x |
|
Arvind Limited
NSE:ARVIND
|
0.111x |
|
KBC Corporation Ltd
SHG:688598
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Chengdu Easton Biopharmaceuticals Co Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of Chengdu Easton Biopharmaceuticals Co Ltd from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.70 Billion | CN¥263.24 Million | 0.098x | -7.71% |
| 2023-12-31 | CN¥2.60 Billion | CN¥275.25 Million | 0.106x | +70.09% |
| 2022-12-31 | CN¥2.44 Billion | CN¥151.94 Million | 0.062x | -3.49% |
| 2021-12-31 | CN¥2.29 Billion | CN¥147.60 Million | 0.064x | -13.79% |
| 2020-12-31 | CN¥2.10 Billion | CN¥156.52 Million | 0.075x | -63.26% |
| 2019-12-31 | CN¥697.44 Million | CN¥141.83 Million | 0.203x | -29.02% |
| 2018-12-31 | CN¥582.19 Million | CN¥166.79 Million | 0.286x | +48.85% |
| 2017-12-31 | CN¥445.28 Million | CN¥85.70 Million | 0.192x | -29.27% |
| 2016-12-31 | CN¥389.79 Million | CN¥106.06 Million | 0.272x | +44.32% |
| 2015-12-31 | CN¥268.21 Million | CN¥50.57 Million | 0.189x | -17.97% |
| 2014-12-31 | CN¥203.25 Million | CN¥46.71 Million | 0.230x | +37.82% |
| 2013-12-31 | CN¥168.62 Million | CN¥28.12 Million | 0.167x | -- |